View Filing Data

Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]

Basis of Presentation, Risks and Uncertainties, and Summary of Significant Accounting Policies

Basis of Presentation

The unaudited consolidated financial statements of Harvard Bioscience, Inc. and its wholly-owned subsidiaries (collectively, Harvard Bioscience or the Company) as of

March 31, 2020

and for the

three

months ended

March 31, 2020

and

2019,

have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) have been condensed or omitted pursuant to such rules and regulations. The

December

31,

2019

consolidated balance sheet was derived from audited financial statements but does

not

include all disclosures required by U.S. GAAP. However, the Company believes that the disclosures are adequate to make the information presented

not

misleading. These unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form

-K for the fiscal year ended

December

31,

2019,

which was filed with the SEC on

March 16, 2020.

In the opinion of management, all adjustments, which include normal recurring adjustments necessary to present a fair statement of financial position as of

March 31, 2020,

results of operations and comprehensive income (loss) for the

three

months ended

March 31, 2020

and

2019

and cash flows for the

three

months ended

March 31, 2020

and

2019,

as applicable, have been made. The results of operations for the

three

months ended

March 31, 2020

are

not

necessarily indicative of the operating results for the full fiscal year or any future periods.

Risks and Uncertainties

March 11, 2020,

the World Health Organization declared the outbreak of a novel coronavirus (COVID-

) as a pandemic. The COVID-

pandemic has had a negative impact on the Company’s operations to date and the future impacts of the pandemic and any resulting economic impact are largely unknown and rapidly evolving. Since the COVID-

outbreak in the United States, Europe and elsewhere, many customers, particularly academic research institutions, have been unable to maintain laboratory work which has, and will continue to, negatively impact our sales. Additionally, to ensure business continuity while maintaining a safe environment for employees aligned with guidance from government and health organizations, the Company transitioned the majority of its workforce to work-from-home while implementing social distancing requirements and other measures in factories to allow manufacturing and other personnel essential to production to continue work within our facilities. Business travel was significantly reduced during this period. While the Company has maintained operations under these conditions, these measures represent disruptions which can impact productivity including sales and marketing activities. Accordingly, these conditions in addition to the overall impact on the global economy has negatively impacted our results of operations and cash flows.

As a result of these market and economic conditions, in accordance with the guidelines set forth in ASC

350

and ASC

360,

the Company performed an analysis for potential interim impairment indicators of its intangible and other long-lived assets. As of

March 31, 2020,

the Company concluded there were

impairments of goodwill, other indefinite-lived intangibles, or long-lived assets that resulted from triggering events due to COVID-

19.

The Company will continue to monitor its assets for potential impairment through the remainder of

2020.

Summary of Significant Accounting Policies

The accounting policies underlying the accompanying unaudited consolidated financial statements are those set forth in Note

to the consolidated financial statements included in the Company’s Annual Report on Form

-K for the year ended

December

31,

2019,

which was filed with the SEC on

March 16, 2020.

There have been

material changes in the Company’s significant accounting policies during the

three

months ended

March 31, 2020.

Note 2 - Recently Issued Accounting Pronouncements

3 Months Ended

Mar. 31, 2020

Description of New Accounting Pronouncements Not yet Adopted [Text Block]

Recently Issued Accounting Pronouncements

Accounting Pronouncements to be Adopted

June 2016,

the FASB issued ASU

No.

2016

13,

Financial Instruments—Credit Losses (Topic

326

): Measurement of Credit Losses on Financial Instruments,

which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses rather than incurred losses to estimate credit losses on certain types of financial instruments, including trade receivables. This

may

result in the earlier recognition of allowances for losses. The FASB issued several ASUs after ASU

2016

to clarify implementation guidance and to provide transition relief for certain entities. ASU

2016

is effective for the Company for fiscal years beginning after

December 15, 2022,

with early adoption permitted. The Company is evaluating the impact of adopting ASU

2016

and related amendments will have on its consolidated financial position, results of operations and cash flows.

August 2018,

the FASB issued ASU

No.

2018

14,

Disclosure Framework—Changes to the Disclosure Requirements for Defined Benefit Plans

, which amends ASC

715

to add, remove and clarify disclosure requirements related to defined benefit pension and other postretirement plans. The ASU is effective for public entities for fiscal years beginning after

December 15, 2020,

with early adoption permitted. Management has

not

yet completed its assessment of the impact of the new standard on the Company’s Consolidated Financial Statements.

December 2019,

the FASB issued ASU

2019

12,

Income Taxes (Topic

740

): Simplifying the Accounting for Income Taxes

, which enhances and simplifies various aspects of the income tax accounting guidance related to intra-period tax allocation, interim period accounting for enacted changes in tax law, and the year-to-date loss limitation in interim period tax accounting. ASU

2019

also amends other aspects of the guidance to reduce complexity in certain areas. ASU

2019

will become effective for the Company on

January 1, 2021.

Early adoption is permitted. The Company is evaluating the impact of adopting this guidance to its financial statements and related disclosures.

Note 3 - Accumulated Other Comprehensive Loss

3 Months Ended

Mar. 31, 2020

Comprehensive Income (Loss) Note [Text Block]

Accumulated Other Comprehensive Loss

Changes in each component of accumulated other comprehensive loss, net of tax are as follows:

	Foreign currency			Derivatives
	translation			qualifying as			Defined benefit
(in thousands)	adjustments			hedges			pension plans		Total

Balance at December 31, 2019	$	(13,173	)	$	(603	)	$	1,087	$	(12,689	)

Other comprehensive (loss) income before reclassifications		(1,576	)		(216	)				(1,792	)
Amounts reclassified from AOCI into Income		-			72					72
Net other comprehensive (loss) income		(1,576	)		(144	)		-		(1,720	)

Balance at March 31, 2020	$	(14,749	)	$	(747	)	$	1,087	$	(14,409	)

Note 4 - Goodwill and Intangible Assets

3 Months Ended

Mar. 31, 2020

Goodwill and Intangible Assets Disclosure [Text Block]

Goodwill and Intangible Assets

Goodwill

The change in the carrying amount of goodwill for the

three

months ended

March 31, 2020

is as follows:

	March 31,
	2020
(in thousands)
Balance at December 31, 2019	$	57,381
Effect of change in currency translation		(589	)
Balance at March 31, 2020	$	56,792

Intangible Assets

			March 31, 2020							December 31, 2019
			(in thousands)
Intangible assets:	Weighted Average Life* (Years)		Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Distribution agreements/customer relationships		8.4	$	17,685	$	(6,550	)	$	11,135	$	17,891	$	(6,340	)	$	11,551
Existing technology		5.5		40,923		(20,327	)		20,596		41,222		(19,698	)		21,524
Trade names		5.3		8,511		(3,667	)		4,844		7,692		(3,497	)		4,195
Patents		-		206		(206	)		-		218		(218	)		-
Indefinite-lived tradename		NA		232		-			232		1,135		0			1,135
Total intangible assets			$	67,557	$	(30,750	)	$	36,807	$	68,158	$	(29,753	)	$	38,405

* Weighted average life as of

March 31, 2020.

During the

three

months ended

March 31, 2020,

the Company determined that

$0.9

million of tradenames previously classified as indefinite-lived should be classified as amortizing due to anticipated changes in worldwide marketing programs and estimated an economic life of

years for this intangible asset.

Intangible asset amortization expense was

$1.4

million for each of the

three

months ended

March 31, 2020

and

2019.

Amortization expense of existing amortizable intangible assets is currently estimated to be

$4.1

million for the remainder of

2020,

$5.5

million for the year ending

December 31, 2021,

$5.5

million for the year ending

December 31, 2022,

$5.3

million for the year ending

December 31, 2023,

$5.3

million for the year ending

December 31, 2024,

and

$4.2

million for the year ending

December 31, 2025.

Note 5 - Inventories

3 Months Ended

Mar. 31, 2020

Inventory Disclosure [Text Block]

Inventories

Inventories consist of the following:

	March 31, 2020		December 31, 2019
	(in thousands)
Finished goods	$	5,280	$	5,561
Work in process		3,160		3,153
Raw materials		14,703		13,347
Total	$	23,143	$	22,061

Note 6 - Property, Plant and Equipment

3 Months Ended

Mar. 31, 2020

Property, Plant and Equipment Disclosure [Text Block]

Property, Plant and Equipment

Property, plant, and equipment consist of the following:

	March 31, 2020			December 31, 2019
	(in thousands)
Machinery and equipment	$	7,437		$	7,198
Computer equipment and software		8,763			8,954
Leasehold improvements		2,157			2,151
Furniture and fixtures		1,309			1,321
Automobiles		90			92
		19,756			19,716
Less: accumulated depreciation		(15,268	)		(14,940	)
Property, plant and equipment, net	$	4,488		$	4,776

Note 7 - Restructuring and Other Exit Costs

3 Months Ended

Mar. 31, 2020

Restructuring and Related Activities Disclosure [Text Block]

Restructuring and Other Exit Costs

During

2019,

the Board of Directors of the Company approved a restructuring program designed to improve gross margins and operating margins while reinvesting in resources required to deliver sustained, profitable organic growth. The restructuring program will entail consolidating and downsizing several sites and includes headcount reductions in Europe and North America to improve operational efficiency and reduce costs.

The restructuring program is expected to be completed by the end of

2020.

The Company expects to incur costs associated with headcount reductions, program management and other transition costs necessary to affect the site consolidations and other business improvements. Substantially all these costs are expected to result in future cash outlays.

The following table summarizes the activity for the accrued restructuring liability for the

three

months ended

March 31, 2020:

(in thousands)	Severance Costs			Other			Total
Balance at December 31, 2019	$	364		$	4		$	368
Restructuring charges		834			40			874
Adjustments		(45	)		-			(45	)
Cash payments		(569	)		(36	)		(605	)
Balance at March 31, 2020	$	584		$	8		$	592

As of

March 31, 2020,

the Company had a restructuring liability of

$0.6

million which is payable within the next

twelve

months and has been included in other current liabilities in the consolidated balance sheet.

Note 8 - Related Party Transactions

3 Months Ended

Mar. 31, 2020

Related Party Transactions

As part of the acquisitions of Multi Channel Systems MCS GmbH (MCS) and Triangle BioSystems, Inc. (TBSI) in

2014,

the Company signed lease agreements with the former owners of these acquired companies. The principals of such former owners of MCS and TBSI became employees of the Company. Pursuant to these lease agreements, the Company made rent payments of approximately

$0.1

million for each of the

three

months ended

March 31, 2020

and

2019.

Note 9 - Employee Benefit Plans

3 Months Ended

Mar. 31, 2020

Retirement Benefits [Text Block]

Employee Benefit Plans

The Company’s subsidiary in the United Kingdom, Biochrom Limited, maintains

two

contributory, defined benefit pension plans that have been closed to new employees since

2014,

as well as closed to the future accrual of benefits for existing participating employees.

For the

three

months ended

March 31, 2020

and

2019,

the Company recorded defined benefit pension expense of

$0.1

million and

$0.2

million, respectively. For each of the

three

months ended

March 31, 2020

and

2019,

the Company contributed

$0.2

million to its defined benefit pension plans. The Company expects to contribute approximately

$0.7

million to its defined benefit pension plans during the remainder of

2020.

As of

December 31, 2019,

the Company pension assets exceeded its pension liability by approximately

$1.1

million that is included in the other long-term asset in the consolidated balance sheets.

The entire disclosure for retirement benefits.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section S99
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (o)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (p)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (q)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (l)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Note 10 - Leases

3 Months Ended

Mar. 31, 2020

Lessee, Operating Leases [Text Block]

10.

Leases

The Company has noncancelable operating leases for office, manufacturing facilities, warehouse space, automobiles and equipment expiring at various dates through

2024

and thereafter.

The components of lease expense for the

three

months ended

March 31, 2020

and

2019

are as follows:

	Three Months Ended			Three Months Ended
	March 31, 2020			March 31, 2019
		(in thousands)			(in thousands)
Operating lease cost	$	535		$	523
Short term lease cost		42			76
Sublease income		(107	)		(102	)
Total lease cost	$	470		$	497

Supplemental cash flow information related to the Company's operating leases was as follows:

	Three Months Ended		Three Months Ended
	March 31, 2020		March 31, 2019
		(in thousands)		(in thousands)
Cash paid for amounts included in the measurement of lease liabilities:	$	687	$	702

Supplemental balance sheet information related to the Company's operating leases was as follows:

	March 31, 2020			December 31, 2019
		(in thousands)			(in thousands)
Operating lease right-of use assets	$	8,127		$	8,463

Current portion, operating lease liabilities	$	2,297		$	2,424
Operating lease liabilities, long term		7,867			8,224
Total operating lease liabilities	$	10,164		$	10,648

Weighted average remaining lease term (in years)		8.0			8.1
Weighted average discount rate		9.2	%		9.2	%

Future minimum lease payments for operating leases, with initial or remaining terms in excess of

one

year at

March 31, 2020,

are as follows:

	Operating
	Leases
	(in thousands)
2021	$	2,297
2022		1,905
2023		1,842
2024		1,827
2025		1,367
Thereafter		5,574
Total lease payments		14,812
Less interest		(4,648	)
Total operating lease liabilities	$	10,164

Note 11 - Capital Stock and Stock-based Compensation

3 Months Ended

Mar. 31, 2020

Shareholders' Equity and Share-based Payments [Text Block]

11.

Capital Stock and Stock-Based Compensation

Employee Stock Purchase Plan (as amended, the ESPP)

Under the Company’s ESPP, participating employees can authorize the Company to withhold a portion of their base pay during consecutive

six

-month payment periods for the purchase of shares of the Company’s common stock. At the conclusion of the period, participating employees can purchase shares of the Company’s common stock at

85%

of the lower of the fair market value of the Company’s common stock at the beginning or end of the period. Shares are issued under the ESPP for the

six

-month periods ending

June 30

and

December 31.

May 16, 2019,

the stockholders of the Company approved an increase of

350,000

shares of common stock in the number of shares available for issuance under the ESPP. Following such amendment,

1,400,000

shares of common stock are authorized for issuance, of which

1,081,404

shares were issued as of

December 31, 2019.

There were

shares issued under the ESPP during the period ended

March 31, 2020.

As of

March 31, 2020,

there were

318,596

shares available for issuance under the plan.

Third Amended and Restated

2000

Stock Option and Incentive Plan (as amended, the Third A&R Plan)

May 25, 2011,

the stockholders of the company approved the Third A&R Plan, which such plan currently authorizes the grant of stock options and stock-based awards to officers, employees, non-employee directors and other key persons of the Company and its subsidiaries. The Third Amendment to the Third A&R Plan (the Amendment) was adopted by the Board of Directors on

April 2, 2018.

Such Amendment was approved by the stockholders at the Company’s

2018

Annual Meeting of Stockholders. Pursuant to the Amendment, the aggregate number of shares authorized for issuance under the Third A&R Plan was increased by

3,400,000

shares to

20,908,929.

As of

March 31, 2020,

there were

275,419

shares available for issuance under the plan

Restricted Stock Units with a Market Condition (the Market Condition RSUs)

2019,

the Compensation Committee of the Board of Directors of the Company approved and granted deferred stock awards of Market Condition RSUs (the

2019

Market Condition RSUs) to certain members of the Company’s management team under the Third A&R Plan. The vesting of the

2019

Market Condition RSUs is based on a graded-vesting schedule (

one

third

at the end of each year for

three

years) and linked to the achievement of a relative total shareholder return of the Company’s common stock measured relative to the Nasdaq Biotechnology index from the

2019

Market Condition RSUs grant date to the earlier of (i) the anniversary date of the grant or (ii) upon a change of control.

As of

March 31, 2020,

the target number of these market condition restricted stock units that

may

be earned is

529,491

shares; the maximum amount is

150%

of the target number.

Stock-Based Payment Awards

The Company accounts for stock-based payment awards in accordance with the provisions of FASB ASC

718,

which requires it to recognize compensation expense for all stock-based payment awards made to employees and directors including stock options, restricted stock units, Market Condition RSUs and employee stock purchases related to the ESPP. The Company has elected as an accounting policy to account for forfeitures for service-based awards as they occur, with

adjustment for estimated forfeitures.

Stock option and restricted stock unit activity for the

three

months ended

March 31, 2020

were as follows:

	Stock Options					Restricted Stock Units					Market Condition RSU's
				Weighted
	Stock			Average		Restricted					Market
	Options			Exercise		Stock Units			Grant Date		Condition RSU's		Grant Date
	Outstanding			Price		Outstanding			Fair Value		Outstanding		Fair Value

Balance at December 31, 2019		2,266,122		$	3.93		1,590,450		$	2.27		529,491	$	1.67
Granted		42,373			2.58		142,766			3.00		-		-
Vested (RSUs)		-			-		(267,588	)		2.75		-		-
Cancelled / forfeited		(49,074	)		3.81		(31,795	)		3.02		-		-
Balance at March 31, 2020		2,259,421		$	3.90		1,433,833		$	2.24		529,491	$	1.67

For the

three

months ended

March 31, 2020,

the total compensation costs related to unvested awards

not

yet recognized is

$3.3

million and the weighted average period over which it is expected to be recognized is approximately

two

years.

Valuation and Expense Information under Stock-Based-Payment Accounting

Stock-based compensation expense for the

three

months ended

March 31, 2020

and

2019

was allocated as follows:

	Three Months Ended March 31,
	2020		2019
	(in thousands)
Cost of product revenues	$	10	$	13
Sales and marketing		51		(7	)
General and administrative		696		551
Research and development		36		34
Total stock-based compensation	$	793	$	591

The Company did

not

capitalize any stock-based compensation.

The weighted-average estimated fair value per share of stock options granted during the

three

months ended

March 31, 2020

was

$1.18

using the Black Scholes option-pricing model with the following weighted-average assumptions:

	2020
Volatility		54.83	%
Risk-free interest rate		1.16	%
Expected holding period (in years)		4.6

The Company used historical volatility to calculate the expected volatility as of

March 31, 2020.

Historical volatility was determined by calculating the mean reversion of the daily adjusted closing stock price. The risk-free interest rate assumption is based upon observed U.S. Treasury bill interest rates (risk-free) appropriate for the term of the Company’s stock options. The expected holding period of stock options represents the period of time options are expected to be outstanding and were based on historical experience. The vesting period ranges from

one

four

years and the contractual life is

ten

years.

Earnings per share

Basic earnings per share is calculated by dividing net income by the number of weighted average common shares outstanding during the period. The calculation of diluted earnings per share assumes conversion of stock options, restricted stock units and Market Condition RSUs into common stock using the treasury method. The weighted average number of shares used to compute basic and diluted earnings per share consists of the following:

	Three Months Ended March 31,
	2020		2019
Basic		38,328,791		37,644,684
Diluted		38,328,791		37,644,684

Excluded from the shares used in calculating the diluted earnings per common share in the above table are options, restricted stock units and Market Condition RSUs of approximately

4,222,745

and

3,691,304

shares of common stock for the

three

months ended

March 31, 2020

and

2019,

respectively, as the impact of these shares would be anti-dilutive.

Note 12 - Long Term Debt

3 Months Ended

Mar. 31, 2020

Long-term Debt [Text Block]

12.

Long term Debt

January 31, 2018,

the Company entered into a financing agreement by and among the Company and certain subsidiaries of the Company as borrowers (collectively, the Borrower), certain subsidiaries of the Company as guarantors, various lenders from time to time (the Lenders), and Cerberus Business Finance, LLC, as collateral agent and administrative agent for the Lenders (the Financing Agreement).

August 16, 2018,

the Company and Cerberus Business Finance, LLC entered into a First Amendment to the Financing Agreement, which such amendment modified certain provisions related to the borrowing base and reporting, among other things. On

November 4, 2019,

the Company and Cerberus Business Finance, LLC entered into a Second Amendment to the Financing Agreement, which modified certain provisions effective as of

September 30, 2019

related to the Company’s quarterly leverage ratio financial covenant amongst other provisions.

The Financing Agreement provided for senior secured credit facilities (the Senior Secured Credit Facilities) comprised of a

$64.0

million term loan and up to a

$25.0

million revolving line of credit subject to available borrowing base. The revolving facility is available for use by the Company and its subsidiaries for general corporate and working capital needs, and other purposes to the extent permitted by the Financing Agreement. Borrowings available under the revolving line of credit are limited to a borrowing base derived from the Company’s eligible accounts receivable and inventory, as defined in the Financing Agreement. As of

March 31, 2020,

borrowings available under the revolving facility were

$4.6

million.

Commencing on

March 31, 2018,

the outstanding term loans began to amortize in equal quarterly installments equal to

$0.4

million per quarter on such date and during each of the next

three

quarters thereafter,

$0.6

million per quarter during the next

four

quarters thereafter and

$0.8

million per quarter thereafter, with a balloon payment at maturity in

2023.

Furthermore, within

ten

days of the Company’s delivery of its audited annual financial statements each year, the term loans are permanently reduced pursuant to certain mandatory prepayment events including an annual “excess cash flow sweep” of

50%

of the consolidated excess cash flow; provided that, in any fiscal year, any voluntary prepayments of the term loans shall be credited against the Company’s “excess cash flow” prepayment obligations on a dollar-for-dollar basis for such fiscal year. During the

three

months ended

March 31, 2020,

the Company made an excess cash flow payment of

$4.0

million. During the year ended

December 31, 2019,

the Company made an excess cash flow payment of

$4.0

million and a payment of

$1.0

million in connection with the release of an escrow amount associated with the Denville Transaction. as required by the Financing Agreement.

The obligations of the Borrower under the Senior Secured Credit Facilities are unconditionally guaranteed by the Company and certain of the Company’s existing and subsequently acquired or organized subsidiaries. The Senior Secured Credit Facilities and related guarantees are secured on a

first

-priority basis (subject to certain liens permitted under the Financing Agreement) by a lien on substantially all the tangible and intangible assets of the Borrower and the subsidiary guarantors, including all of the capital stock held by such obligors (subject to a

65%

limitation on pledges of capital stock of foreign subsidiaries), subject to certain exceptions.

Interest on all loans under the Senior Secured Credit Facilities is paid monthly. Borrowings under the Financing Agreement accrue interest at a per annum rate equal to, at the Borrower’s option, a base rate plus

4.75%

or a London Interbank Offered Rate (LIBOR) rate plus

6.25%.

The loans are also subject to a

1.25%

interest rate floor for LIBOR loans and a

4.25%

interest rate floor for base rate loans. The LIBOR index is expected to be discontinued by the end of calendar year

2021.

The terms of the revolving credit facility allow for a replacement rate if the LIBOR index is discontinued.

The Financing Agreement contains customary representations and warranties and affirmative covenants applicable to the Company and its subsidiaries and also contains certain restrictive covenants, including, among others, limitations on the incurrence of additional debt, liens on property, acquisitions and investments, loans and guarantees, mergers, consolidations, liquidations and dissolutions, asset sales, dividends and other payments in respect of the Company’s capital stock, prepayments of certain debt, transactions with affiliates and modifications of organizational documents, material contracts, affiliated practice agreements and certain debt agreements. The Financing Agreement contains customary events of default and is subject to covenant and working capital borrowing restrictions.

The Company is compliant with all covenants under the Financing Agreement as of

March 31, 2020.

The Company’s covenants include a requirement to maintain a maximum leverage ratio among other financial and non-financial covenants, as defined in the Financing Agreement. The maximum permitted leverage is the ratio of total debt to consolidated EBITDA, as defined in the Financing Agreement, with a maximum ratio of

3.50

as of

March 31, 2020,

stepping down to

3.25

for the

three

months ended

June 30, 2020

and all quarters thereafter. Due to the negative impact of COVID-

on revenue and consolidated EBITDA, the Company’s leverage ratio has increased, and the gap between the leverage ratio and maximum permitted leverage has reduced.

Based on the Company’s current operating plans, including actions taken to mitigate the impact of COVID-

19,

it expects that available cash, cash generated from current operations and debt capacity will be sufficient to finance current operations, any costs associated with restructuring activities and capital expenditures. This assessment includes consideration of the Company’s best estimates of the impact of the COVID-

pandemic on its financial results. If the negative impact of COVID-

is more significant than anticipated it

may

impact the Company’s ability to comply with financial covenants in the future, which would require the Company to seek an amendment or waivers from its lenders, limit access to or require accelerated repayment of the existing credit facilities, or require the Company to pursue alternative financing. There are

assurances that any such alternative financing, if required, could be obtained at terms acceptable to the Company, or at all.

As of

March 31, 2020,

the weighted effective interest rate, net of the impact of the Company’s interest rate swap, on its borrowings was

8.40%.

The carrying value of the debt approximates fair value because the interest rate under the obligation approximates market rates of interest available to the Company for similar instruments.

As of

March 31, 2020,

and

December 31, 2019,

the Company’s borrowings were comprised of:

	March 31,			December 31,
	2020			2019
	(in thousands)
Long-term debt:
Term loan	$	50,168			54,997
Revolving line		-			-
Total unamortized deferred financing costs		(1,081	)		(1,180	)
Total debt		49,087			53,817
Less: current installments		(3,200	)		(3,200	)
Less: excess cash flow sweep		-			(4,093	)
Current unamortized deferred financing costs		393			393
Long-term debt	$	46,280		$	46,917

Note 13 - Derivatives

3 Months Ended

Mar. 31, 2020

Derivative Instruments and Hedging Activities Disclosure [Text Block]

13.

Derivatives

The Company uses interest-rate-related derivative instruments to manage its exposure related to changes in interest rates on its variable-rate debt instruments. The Company does

not

enter into derivative instruments for any purpose other than cash flow hedging. The Company does

not

speculate using derivative instruments.

By using derivative financial instruments to hedge exposures to changes in interest rates, the Company exposes itself to credit risk and market risk. Credit risk is the failure of the counterparty to perform under the terms of the derivative contract. When the fair value of a derivative contract is positive, the counterparty owes the Company, which creates credit risk for the Company. When the fair value of a derivative contract is negative, the Company owes the counterparty and, therefore, the Company is

not

exposed to the counterparty’s credit risk in those circumstances. The Company minimizes counterparty credit risk in derivative instruments by entering into transactions with carefully selected major financial institutions based upon their credit profile.

Market risk is the adverse effect on the value of a derivative instrument that results from a change in interest rates. The market risk associated with interest-rate contracts is managed by establishing and monitoring parameters that limit the types and degree of market risk that

may

be undertaken.

The Company assesses interest rate risk by continually identifying and monitoring changes in interest rate exposures that

may

adversely impact expected future cash flows and by evaluating hedging opportunities. The Company maintains risk management control systems to monitor interest rate risk attributable to both the Company’s outstanding and forecasted debt obligations as well as the Company’s offsetting hedge positions. The risk management control systems involve the use of analytical techniques, including cash flow sensitivity analysis, to estimate the expected impact of changes in interest rates on the Company’s future cash flows.

The Company uses variable-rate LIBOR debt to finance its operations. The debt obligations expose the Company to variability in interest payments due to changes in interest rates. Management believes that it is prudent to limit the variability of a portion of its interest payments. To meet this objective, management enters into LIBOR based interest rate swap agreements to manage fluctuations in cash flows resulting from changes in the benchmark interest rate of LIBOR. These swaps change the variable-rate cash flow exposure on the debt obligations to fixed cash flows. Under the terms of the interest rate swaps, the Company receives LIBOR based variable interest rate payments and makes fixed interest rate payments, thereby creating the equivalent of fixed-rate debt for the notional amount of its debt hedged.

As disclosed in Note

12,

January 31, 2018,

the Company entered into a Financing Agreement comprised of a

$64.0

million term loan and up to a

$25.0

million revolving line of credit. Shortly after entering into this Financing Agreement, the Company entered into an interest rate swap contract with PNC Bank with a notional amount of

$36.0

million and a termination date of

January 1, 2023

in order to hedge the risk of changes in the effective benchmark interest rate (LIBOR) associated with the Company’s Term Loan. The swap contract converted specific variable-rate debt into fixed-rate debt and fixed the LIBOR rate associated with a portion of the term loan under the Financing Agreement at

2.72%.

The interest rate swap was designated as a cash flow hedge instrument in accordance with ASC

815

“Derivatives and Hedging”.

The following table presents the notional amount and fair value of the Company’s derivative instruments as of

March 31, 2020

and

December 31, 2019.

		March 31, 2020
		Notional Amount		Fair Value (a)
Derivatives instruments	Balance sheet classification		(in thousands)
Interest rate swaps	Other long term liabilities	$	27,289	$	(747	)

		December 31, 2019
		Notional Amount		Fair Value (a)
Derivatives instruments	Balance sheet classification		(in thousands)
Interest rate swaps	Other long term liabilities	$	28,821	$	(603	)

(a) See Note

for the fair value measurements related to these financial instruments.

All of the Company’s derivative instruments are designated as hedging instruments. The Company has structured its interest rate swap agreements to be

100%

effective and as a result, there was

impact to earnings resulting from hedge ineffectiveness. Changes in the fair value of interest rate swaps designated as hedging instruments that effectively offset the variability of cash flows associated with variable-rate, long-term debt obligations are reported in accumulated other comprehensive income (AOCI). These amounts subsequently are reclassified into interest expense as a yield adjustment of the hedged interest payments in the same period in which the related interest affects earnings. The Company’s interest rate swap agreement was deemed to be fully effective in accordance with ASC

815,

and, as such, unrealized gains and losses related to these derivatives were recorded as AOCI.

The following table summarizes the effect of derivatives designated as cash flow hedging instruments and their classification within comprehensive loss for the

three

months ended

March 31, 2020

and

2019:

Derivatives in Hedging Relationships	Amount of gain (loss) recognized in OCI on derivative (effective portion)
	Three Months Ended March 31,
	2020			2019
	(in thousands)
Interest rate swaps	$	(216	)	$	(196	)

The following table summarizes the reclassifications out of accumulated other comprehensive loss for the

three

months ended

March 31, 2020

and

2019:

Details about AOCI Components	Amount reclassified from AOCI into income (effective portion)
	Three Months Ended March 31,				Location of amount reclassified from AOCI
	2020		2019		into income (effective portion)
	(in thousands)
Interest rate swaps	$	72	$	17	Interest expense

As of

March 31, 2020,

$0.4

million of deferred losses on derivative instruments accumulated in AOCI are expected to be reclassified to earnings during the next

twelve

months. Transactions and events expected to occur over the next

twelve

months that will necessitate reclassifying these derivatives’ losses to earnings include the repricing of variable-rate debt.

Note 14 - Fair Value Measurement

3 Months Ended

Mar. 31, 2020

Fair Value Disclosures [Text Block]

14.

Fair Value Measurement

Fair value measurement is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy is established, which prioritizes the inputs used in measuring fair value into

three

broad levels as follows:

Level

1—Quoted

prices in active markets for identical assets or liabilities.

Level

2—Inputs,

other than the quoted prices in active markets, that are observable either directly or indirectly.

Level

3—Unobservable

inputs based on the Company’s own assumptions.

The following tables present the fair value hierarchy for those assets or liabilities measured at fair value on a recurring basis:

	Fair Value as of March 31, 2020
(in thousands)	Level 1		Level 2			Level 3		Total
Assets (Liabilities):
Interest rate swap agreements	$	-	$	(747	)	$	-	$	(747	)

	Fair Value as of December 31, 2019
(in thousands)	Level 1		Level 2			Level 3		Total
Assets (Liabilities):
Interest rate swap agreements	$	-	$	(603	)	$	-	$	(603	)

The Company uses the market approach technique to value its financial liabilities. The Company’s financial assets and liabilities carried at fair value include derivative instruments used to hedge the Company’s interest rate risks. The fair value of the Company’s interest rate swap agreements was based on LIBOR yield curves at the reporting date.

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

Note 15 - Other Current Liabilities

3 Months Ended

Mar. 31, 2020

Accrued Expenses Disclosure [Text Block]

15.

Other Current Liabilities

	March 31,		December 31,
	2020		2019
	(in thousands)
Compensation and payroll	$	2,896	$	2,554
Professional fees		567		395
Warranty costs		201		252
Local taxes, including VAT		91		345
Customer related costs		1,179		963
Interest		490		425
Other		2,025		1,157
Total	$	7,449	$	6,091

Note 16 - Revenues

3 Months Ended

Mar. 31, 2020

Revenue from Contract with Customer [Text Block]

16.

Revenues

The following table represents a disaggregation of revenue from contracts with customers. Revenue originating from the following geographic areas for the

three

months ended

March 31, 2020

and

2019

consist of:

	Three Months Ended March 31, 2020
	(in thousands)
	United States		United Kingdom		Germany		Rest of the world		Total
Instruments, equipment, software and accessories	$	15,956	$	2,507	$	2,573	$	1,901	$	22,937
Service, maintenance and warranty contracts		575		204		39		16		834
Total revenues	$	16,531	$	2,711	$	2,612	$	1,917	$	23,771

	Three Months Ended March 31, 2019
	(in thousands)
	United States		United Kingdom		Germany		Rest of the world		Total
Instruments, equipment, software and accessories	$	18,671	$	3,129	$	2,913	$	2,044	$	26,757
Service, maintenance and warranty contracts		1,143		190		97		15		1,445
Total revenues	$	19,814	$	3,319	$	3,010	$	2,059	$	28,202

Deferred revenue

The Company had approximately

$3.7

million in deferred revenue from service contracts and advance payments as of

March 31, 2020

and

2019,

respectively. Changes in deferred revenue from service contracts and advance payments from customers during the period were as follows:

	Three Months Ended March 31, 2020
	(in thousands)
	Service Contracts			Customer Advances			Total
Balance, beginning of period	$	1,587		$	2,362		$	3,949
Deferral of revenue		308			223			531
Recognition of deferred revenue		(499	)		(322	)		(821	)
Effect of foreign currency translation		14			-			14
Balance, end of period	$	1,410		$	2,263		$	3,673

	Three Months Ended March 31, 2019
	(in thousands)
	Service Contracts			Customer Advances			Total
Balance, beginning of period	$	1,659		$	2,161		$	3,820
Deferral of revenue		845			111			956
Recognition of deferred revenue		(848	)		(223	)		(1,071	)
Effect of foreign currency translation		10			-			10
Balance, end of period	$	1,666		$	2,049		$	3,715

Allowance for Doubtful Accounts

Allowance for doubtful accounts is based on the Company’s assessment of the collectability of accounts receivable. A rollforward of allowance for doubtful accounts is as follows:

	Three Months Ended March 31,
	2020			2019
	(in thousands)
Balance, beginning of period	$	325		$	332
Bad debt expense		4			348
Charge-offs and other recoveries		(31	)		(337	)
Effect of foreign currency translation		(1	)		(2	)
Balance, end of period	$	297		$	341

Concentrations

customer accounted for more than

10%

of the revenues for the

three

months ended

March 31, 2020,

and

2019.

March 31, 2020,

and

2019,

customer accounted for more than

10%

of net accounts receivable.

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Note 17 - Income Tax

3 Months Ended

Mar. 31, 2020

Income Tax Disclosure [Text Block]

17.

Income Tax

Income tax expense was approximately

$0.1

million and

$0.6

million for the

three

months ended

March 31, 2020

and

2019,

respectively. The effective tax rate was (

1.2

) % for the

three

months ended

March 31, 2020

compared with (

32.1

) % for the same period in

2019.

The difference between the Company’s effective tax rates in

2020

and

2019

compared to the U.S. statutory tax rate of

21%

is primarily due to the mix of

2020

forecasted income or losses in the U.S. and foreign tax jurisdictions, the impact of different tax rates in certain foreign jurisdictions and the impact of the inclusion of foreign income in U.S. taxable income under the GILTI (Global Intangible Low-Taxed Income) tax rules. Changes made by the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) to the limitation on interest expense deductions, including a retroactive change to the calendar year

2019

deduction, also impacted the

2020

effective tax rate.

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

Note 18 - Commitments and Contingent Liabilities

3 Months Ended

Mar. 31, 2020

Commitments and Contingencies Disclosure [Text Block]

18.

Commitments and Contingent Liabilities

April 14, 2017,

representatives for the estate of an individual plaintiff filed a wrongful death complaint with the Suffolk Superior Court, in the County of Suffolk, Massachusetts, against the Company and other defendants, including Biostage, Inc. (f/k/a Harvard Apparatus Regenerative Technology, Inc.), the Company’s former subsidiary that was spun off in

2013,

as well as another

third

party. The complaint seeks payment for an unspecified amount of damages and alleges that the plaintiff sustained terminal injuries allegedly caused by products, including synthetic trachea scaffolds and bioreactors, provided by certain of the named defendants and utilized in connection with surgeries performed by

third

parties in

2012

and

2013.

The litigation is at an early stage and the Company intends to vigorously defend this case and has contacted its liability insurance carrier to request defense and indemnification of any losses incurred in connection with this lawsuit. While the Company believes that such claim is without merit, the Company is unable to predict the ultimate outcome of this litigation.

The Company is involved in various other claims and legal proceedings arising in the ordinary course of business. Based on the consultation with the Company’s legal counsel, the ultimate disposition of such proceedings is

not

likely to have a material adverse effect on the Company’s business, financial condition, results of operations or cash flows. The Company has

not

accrued for loss contingencies relating to any such matters because the Company believes that, although unfavorable outcomes in the proceedings are possible, they are

not

considered by management to be probable and reasonably estimable. If

one

or more of these matters are resolved in a manner adverse to the Company, the impact on its business, financial condition, results of operations and cash flows could be material.

Note 19 - Subsequent Event

3 Months Ended

Mar. 31, 2020

Subsequent Events [Text Block]

19.

Subsequent Event

April 18, 2020,

the Company entered into a promissory note (the “Note”) with PNC Bank, National Association (the “Lender”), which provides for a loan in the amount of

$6.1

million (the “PPP Loan”) pursuant to the Paycheck Protection Program (the “PPP”) of the CARES Act administered by the U.S. Small Business Administration (the “SBA”).

April 23, 2020,

the SBA, in consultation with the U.S. Department of the Treasury issued guidance regarding consideration of alternate available sources of liquidity and its impact on qualification for PPP loans. The Company reassessed its business plans and liquidity available under its existing credit facility and determined it was appropriate to repay funds received under the PPP Loan. The PPP Loan was repaid in full on

May 4, 2020.

Significant Accounting Policies (Policies)	3 Months Ended
Significant Accounting Policies (Policies)	Mar. 31, 2020
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The unaudited consolidated financial statements of Harvard Bioscience, Inc. and its wholly-owned subsidiaries (collectively, Harvard Bioscience or the Company) as of March 31, 2020 and for the three months ended March 31, 2020 and 2019, have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) have been condensed or omitted pursuant to such rules and regulations. The December 31, 2019 consolidated balance sheet was derived from audited financial statements but does not include all disclosures required by U.S. GAAP. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10 -K for the fiscal year ended December 31, 2019, which was filed with the SEC on March 16, 2020. In the opinion of management, all adjustments, which include normal recurring adjustments necessary to present a fair statement of financial position as of March 31, 2020, results of operations and comprehensive income (loss) for the three months ended March 31, 2020 and 2019 and cash flows for the three months ended March 31, 2020 and 2019, as applicable, have been made. The results of operations for the three months ended March 31, 2020 are not necessarily indicative of the operating results for the full fiscal year or any future periods.
Risk and Uncertainties Policy [Policy Text Block]	Risks and Uncertainties On March 11, 2020, the World Health Organization declared the outbreak of a novel coronavirus (COVID- 19 ) as a pandemic. The COVID- 19 pandemic has had a negative impact on the Company’s operations to date and the future impacts of the pandemic and any resulting economic impact are largely unknown and rapidly evolving. Since the COVID- 19 outbreak in the United States, Europe and elsewhere, many customers, particularly academic research institutions, have been unable to maintain laboratory work which has, and will continue to, negatively impact our sales. Additionally, to ensure business continuity while maintaining a safe environment for employees aligned with guidance from government and health organizations, the Company transitioned the majority of its workforce to work-from-home while implementing social distancing requirements and other measures in factories to allow manufacturing and other personnel essential to production to continue work within our facilities. Business travel was significantly reduced during this period. While the Company has maintained operations under these conditions, these measures represent disruptions which can impact productivity including sales and marketing activities. Accordingly, these conditions in addition to the overall impact on the global economy has negatively impacted our results of operations and cash flows. As a result of these market and economic conditions, in accordance with the guidelines set forth in ASC 350 and ASC 360, the Company performed an analysis for potential interim impairment indicators of its intangible and other long-lived assets. As of March 31, 2020, the Company concluded there were no impairments of goodwill, other indefinite-lived intangibles, or long-lived assets that resulted from triggering events due to COVID- 19. The Company will continue to monitor its assets for potential impairment through the remainder of 2020.

Note 3 - Accumulated Other Comprehensive Loss (Tables)

3 Months Ended

Mar. 31, 2020

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

	Foreign currency			Derivatives
	translation			qualifying as			Defined benefit
(in thousands)	adjustments			hedges			pension plans		Total

Balance at December 31, 2019	$	(13,173	)	$	(603	)	$	1,087	$	(12,689	)

Other comprehensive (loss) income before reclassifications		(1,576	)		(216	)				(1,792	)
Amounts reclassified from AOCI into Income		-			72					72
Net other comprehensive (loss) income		(1,576	)		(144	)		-		(1,720	)

Balance at March 31, 2020	$	(14,749	)	$	(747	)	$	1,087	$	(14,409	)

Note 4 - Goodwill and Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2020

Schedule of Goodwill [Table Text Block]

	March 31,
	2020
(in thousands)
Balance at December 31, 2019	$	57,381
Effect of change in currency translation		(589	)
Balance at March 31, 2020	$	56,792

Schedule of Intangible Assets and Goodwill [Table Text Block]

			March 31, 2020							December 31, 2019
			(in thousands)
Intangible assets:	Weighted Average Life* (Years)		Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Distribution agreements/customer relationships		8.4	$	17,685	$	(6,550	)	$	11,135	$	17,891	$	(6,340	)	$	11,551
Existing technology		5.5		40,923		(20,327	)		20,596		41,222		(19,698	)		21,524
Trade names		5.3		8,511		(3,667	)		4,844		7,692		(3,497	)		4,195
Patents		-		206		(206	)		-		218		(218	)		-
Indefinite-lived tradename		NA		232		-			232		1,135		0			1,135
Total intangible assets			$	67,557	$	(30,750	)	$	36,807	$	68,158	$	(29,753	)	$	38,405

Note 5 - Inventories (Tables)

3 Months Ended

Mar. 31, 2020

Schedule of Inventory, Current [Table Text Block]

	March 31, 2020		December 31, 2019
	(in thousands)
Finished goods	$	5,280	$	5,561
Work in process		3,160		3,153
Raw materials		14,703		13,347
Total	$	23,143	$	22,061

Note 6 - Property, Plant and Equipment (Tables)

3 Months Ended

Mar. 31, 2020

Property, Plant and Equipment [Table Text Block]

	March 31, 2020			December 31, 2019
	(in thousands)
Machinery and equipment	$	7,437		$	7,198
Computer equipment and software		8,763			8,954
Leasehold improvements		2,157			2,151
Furniture and fixtures		1,309			1,321
Automobiles		90			92
		19,756			19,716
Less: accumulated depreciation		(15,268	)		(14,940	)
Property, plant and equipment, net	$	4,488		$	4,776

Note 7 - Restructuring and Other Exit Costs (Tables)

3 Months Ended

Mar. 31, 2020

Schedule of Restructuring Reserve by Type of Cost [Table Text Block]

(in thousands)	Severance Costs			Other			Total
Balance at December 31, 2019	$	364		$	4		$	368
Restructuring charges		834			40			874
Adjustments		(45	)		-			(45	)
Cash payments		(569	)		(36	)		(605	)
Balance at March 31, 2020	$	584		$	8		$	592

Note 10 - Leases (Tables)

3 Months Ended

Mar. 31, 2020

Lease, Cost [Table Text Block]

	Three Months Ended			Three Months Ended
	March 31, 2020			March 31, 2019
		(in thousands)			(in thousands)
Operating lease cost	$	535		$	523
Short term lease cost		42			76
Sublease income		(107	)		(102	)
Total lease cost	$	470		$	497

Supplemental Cash Flow Information Related to Operating Leases [Table Text Block]

	Three Months Ended		Three Months Ended
	March 31, 2020		March 31, 2019
		(in thousands)		(in thousands)
Cash paid for amounts included in the measurement of lease liabilities:	$	687	$	702

Supplemental Balance Sheet Informaton Related to Operating Leases [Table Text Block]

	March 31, 2020			December 31, 2019
		(in thousands)			(in thousands)
Operating lease right-of use assets	$	8,127		$	8,463

Current portion, operating lease liabilities	$	2,297		$	2,424
Operating lease liabilities, long term		7,867			8,224
Total operating lease liabilities	$	10,164		$	10,648

Weighted average remaining lease term (in years)		8.0			8.1
Weighted average discount rate		9.2	%		9.2	%

Lessee, Operating Lease, Liability, Maturity [Table Text Block]

	Operating
	Leases
	(in thousands)
2021	$	2,297
2022		1,905
2023		1,842
2024		1,827
2025		1,367
Thereafter		5,574
Total lease payments		14,812
Less interest		(4,648	)
Total operating lease liabilities	$	10,164

Note 11 - Capital Stock and Stock-based Compensation (Tables)

3 Months Ended

Mar. 31, 2020

Schedule Of Stock Options And Restricted Stock Units Activity Roll forward [Table Text Block]

	Stock Options					Restricted Stock Units					Market Condition RSU's
				Weighted
	Stock			Average		Restricted					Market
	Options			Exercise		Stock Units			Grant Date		Condition RSU's		Grant Date
	Outstanding			Price		Outstanding			Fair Value		Outstanding		Fair Value

Balance at December 31, 2019		2,266,122		$	3.93		1,590,450		$	2.27		529,491	$	1.67
Granted		42,373			2.58		142,766			3.00		-		-
Vested (RSUs)		-			-		(267,588	)		2.75		-		-
Cancelled / forfeited		(49,074	)		3.81		(31,795	)		3.02		-		-
Balance at March 31, 2020		2,259,421		$	3.90		1,433,833		$	2.24		529,491	$	1.67

Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

	Three Months Ended March 31,
	2020		2019
	(in thousands)
Cost of product revenues	$	10	$	13
Sales and marketing		51		(7	)
General and administrative		696		551
Research and development		36		34
Total stock-based compensation	$	793	$	591

Schedule of Weighted Average Number of Shares [Table Text Block]

	Three Months Ended March 31,
	2020		2019
Basic		38,328,791		37,644,684
Diluted		38,328,791		37,644,684

Black Scholes Option Pricing Model [Member]

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	2020
Volatility		54.83	%
Risk-free interest rate		1.16	%
Expected holding period (in years)		4.6

Note 12 - Long Term Debt (Tables)

3 Months Ended

Mar. 31, 2020

Schedule of Debt [Table Text Block]

	March 31,			December 31,
	2020			2019
	(in thousands)
Long-term debt:
Term loan	$	50,168			54,997
Revolving line		-			-
Total unamortized deferred financing costs		(1,081	)		(1,180	)
Total debt		49,087			53,817
Less: current installments		(3,200	)		(3,200	)
Less: excess cash flow sweep		-			(4,093	)
Current unamortized deferred financing costs		393			393
Long-term debt	$	46,280		$	46,917

Note 13 - Derivatives (Tables)

3 Months Ended

Mar. 31, 2020

Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]

		March 31, 2020
		Notional Amount		Fair Value (a)
Derivatives instruments	Balance sheet classification		(in thousands)
Interest rate swaps	Other long term liabilities	$	27,289	$	(747	)

		December 31, 2019
		Notional Amount		Fair Value (a)
Derivatives instruments	Balance sheet classification		(in thousands)
Interest rate swaps	Other long term liabilities	$	28,821	$	(603	)

Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]

Derivatives in Hedging Relationships	Amount of gain (loss) recognized in OCI on derivative (effective portion)
	Three Months Ended March 31,
	2020			2019
	(in thousands)
Interest rate swaps	$	(216	)	$	(196	)

Details about AOCI Components	Amount reclassified from AOCI into income (effective portion)
	Three Months Ended March 31,				Location of amount reclassified from AOCI
	2020		2019		into income (effective portion)
	(in thousands)
Interest rate swaps	$	72	$	17	Interest expense

Note 14 - Fair Value Measurement (Tables)

3 Months Ended

Mar. 31, 2020

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

	Fair Value as of March 31, 2020
(in thousands)	Level 1		Level 2			Level 3		Total
Assets (Liabilities):
Interest rate swap agreements	$	-	$	(747	)	$	-	$	(747	)

	Fair Value as of December 31, 2019
(in thousands)	Level 1		Level 2			Level 3		Total
Assets (Liabilities):
Interest rate swap agreements	$	-	$	(603	)	$	-	$	(603	)

Note 15 - Other Current Liabilities (Tables)

3 Months Ended

Mar. 31, 2020

Schedule of Accrued Liabilities [Table Text Block]

	March 31,		December 31,
	2020		2019
	(in thousands)
Compensation and payroll	$	2,896	$	2,554
Professional fees		567		395
Warranty costs		201		252
Local taxes, including VAT		91		345
Customer related costs		1,179		963
Interest		490		425
Other		2,025		1,157
Total	$	7,449	$	6,091

Note 16 - Revenues (Tables)

3 Months Ended

Mar. 31, 2020

Disaggregation of Revenue [Table Text Block]

	Three Months Ended March 31, 2020
	(in thousands)
	United States		United Kingdom		Germany		Rest of the world		Total
Instruments, equipment, software and accessories	$	15,956	$	2,507	$	2,573	$	1,901	$	22,937
Service, maintenance and warranty contracts		575		204		39		16		834
Total revenues	$	16,531	$	2,711	$	2,612	$	1,917	$	23,771

	Three Months Ended March 31, 2019
	(in thousands)
	United States		United Kingdom		Germany		Rest of the world		Total
Instruments, equipment, software and accessories	$	18,671	$	3,129	$	2,913	$	2,044	$	26,757
Service, maintenance and warranty contracts		1,143		190		97		15		1,445
Total revenues	$	19,814	$	3,319	$	3,010	$	2,059	$	28,202

Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]

	Three Months Ended March 31, 2020
	(in thousands)
	Service Contracts			Customer Advances			Total
Balance, beginning of period	$	1,587		$	2,362		$	3,949
Deferral of revenue		308			223			531
Recognition of deferred revenue		(499	)		(322	)		(821	)
Effect of foreign currency translation		14			-			14
Balance, end of period	$	1,410		$	2,263		$	3,673

	Three Months Ended March 31, 2019
	(in thousands)
	Service Contracts			Customer Advances			Total
Balance, beginning of period	$	1,659		$	2,161		$	3,820
Deferral of revenue		845			111			956
Recognition of deferred revenue		(848	)		(223	)		(1,071	)
Effect of foreign currency translation		10			-			10
Balance, end of period	$	1,666		$	2,049		$	3,715

Financing Receivable, Allowance for Credit Loss [Table Text Block]

	Three Months Ended March 31,
	2020			2019
	(in thousands)
Balance, beginning of period	$	325		$	332
Bad debt expense		4			348
Charge-offs and other recoveries		(31	)		(337	)
Effect of foreign currency translation		(1	)		(2	)
Balance, end of period	$	297		$	341

Note 1 - Basis of Presentation, Risks and Uncertainties, and Summary of Significant Accounting Policies (Details Textual) $ in Thousands	3 Months Ended
	Mar. 31, 2020 USD ($)
COVID-19 [Member]
Asset Impairment Charges, Total	$ 0

Note 3 - Accumulated Other Comprehensive Loss - Changes in Each Component of Other Comprehensive Loss, Net of Tax (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Balance	$ 81,694	$ 82,724
Other comprehensive (loss)	(1,720)	(175)
Balance	76,009	80,349
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Balance	(13,173)
Other comprehensive (loss) income before reclassifications	(1,576)
Amounts reclassified from AOCI into Income
Other comprehensive (loss)	(1,576)
Balance	(14,749)
Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]
Balance	(603)
Other comprehensive (loss) income before reclassifications	(216)
Amounts reclassified from AOCI into Income	72
Other comprehensive (loss)	(144)
Balance	(747)
Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]
Balance	1,087
Other comprehensive (loss) income before reclassifications
Amounts reclassified from AOCI into Income
Other comprehensive (loss)
Balance	1,087
AOCI Attributable to Parent [Member]
Balance	(12,689)	(13,532)
Other comprehensive (loss) income before reclassifications	(1,792)
Amounts reclassified from AOCI into Income	72
Other comprehensive (loss)	(1,720)	(175)
Balance	$ (14,409)	$ (13,707)

Amount after tax and reclassification adjustments of other comprehensive income (loss).

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

Note 4 - Goodwill and Intangible Assets (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Amortization of Intangible Assets, Total	$ 1,427	$ 1,430
Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year	4,100
Finite-Lived Intangible Asset, Expected Amortization, Year Two	5,500
Finite-Lived Intangible Asset, Expected Amortization, Year Three	5,500
Finite-Lived Intangible Asset, Expected Amortization, Year Four	5,300
Finite-Lived Intangible Asset, Expected Amortization, Year Five	5,300
Finite-Lived Intangible Asset, Expected Amortization, Year Six	4,200
Indefinite-Lived Trade Names Reclassified to Finite-Lived [Member]
Reclassification of Intangible Assets	$ 900
Finite-Lived Intangible Asset, Useful Life (Year)	4 years

Note 4 - Goodwill and Intangible Assets - Change in Carrying Amount of Goodwill (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020 USD ($)
Balance at December 31, 2019	$ 57,381
Effect of change in currency translation	(589)
Balance at March 31, 2020	$ 56,792

Note 4 - Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2020

Dec. 31, 2019

Indefinite-lived tradename

$ (30,750)

$ (29,753)

232

1,135

Total Intangible Assets, Gross

67,557

68,158

Intangible assets, net

$ 36,807

38,405

Distribution Agreements/Customer Relationships [Member]

Finite-Lived Intangible Assets, Weighted Average Useful Life (Year)

^[1]

8 years 146 days

$ 17,685

17,891

(6,550)

(6,340)

Existing Technology [Member]

$ 11,135

11,551

Finite-Lived Intangible Assets, Weighted Average Useful Life (Year)

^[1]

5 years 182 days

$ 40,923

41,222

(20,327)

(19,698)

Finite-Lived Intangible Assets, Weighted Average Useful Life (Year)

$ 20,596

21,524

Trade Names [Member]

^[1]

5 years 109 days

$ 8,511

7,692

(3,667)

(3,497)

4,844

4,195

Patents [Member]

206

218

(206)

(218)

[1]	Weighted average life as of March 31, 2020.

Note 5 - Inventories - Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Finished goods	$ 5,280	$ 5,561
Work in process	3,160	3,153
Raw materials	14,703	13,347
Total	$ 23,143	$ 22,061

Note 6 - Property, Plant and Equipment - Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment, Gross	$ 19,756	$ 19,716
Less: accumulated depreciation	(15,268)	(14,940)
Property, plant and equipment, net	4,488	4,776
Machinery and Equipment [Member]
Property, Plant and Equipment, Gross	7,437	7,198
Computer Equipment and Software [member]
Property, Plant and Equipment, Gross	8,763	8,954
Leasehold Improvements [Member]
Property, Plant and Equipment, Gross	2,157	2,151
Furniture and Fixtures [Member]
Property, Plant and Equipment, Gross	1,309	1,321
Automobiles [Member]
Property, Plant and Equipment, Gross	$ 90	$ 92

Note 7 - Restructuring and Other Exit Costs (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Restructuring Reserve, Ending Balance	$ 592	$ 368

Note 7 - Restructuring and Other Exit Costs - Activity for Accrued Restructuring Liability (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020 USD ($)
Balance at December 31, 2019	$ 368
Restructuring charges	874
Adjustments	(45)
Cash payments	(605)
Balance at March 31, 2020	592
Employee Severance [Member]
Balance at December 31, 2019	364
Restructuring charges	834
Adjustments	(45)
Cash payments	(569)
Balance at March 31, 2020	584
Other Restructuring [Member]
Balance at December 31, 2019	4
Restructuring charges	40
Adjustments
Cash payments	(36)
Balance at March 31, 2020	$ 8

Note 8 - Related Party Transactions (Details Textual) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Multi Channel Systems MCS GmbH [Member]
Operating Leases, Rent Expense, Net, Total	$ 0.1	$ 0.1

Note 9 - Employee Benefit Plans (Details Textual) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Defined Contribution Plan, Cost	$ 0.1	$ 0.2
Defined Benefit Plan, Plan Assets, Contributions by Employer	0.2
Defined Benefit Plan, Expected Future Benefit Payment, Year Four	0.7
Other Noncurrent Assets [Member]
Defined Benefit Plan, Plan Assets, Amount, Ending Balance	$ 1.1

Amount of contribution received by defined benefit plan from employer which increases plan assets.

Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.

Other Noncurrent Liabilities [Member]

Note 10 - Leases - Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating lease cost	$ 535	$ 523
Short term lease cost	42	76
Sublease income	(107)	(102)
Total lease cost	$ 470	$ 497

Note 10 - Leases - Supplemental Cash Flow Information Related to Operating Leases (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash paid for amounts included in the measurement of lease liabilities:	$ 687	$ 702

Note 10 - Leases - Supplemental Balance Sheet Information Related to Operating Leases (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Operating lease right-of use assets	$ 8,127	$ 8,463
Current portion, operating lease liabilities	2,297	2,424
Operating lease liabilities, long term	7,867	8,224
Total operating lease liabilities	$ 10,164	$ 10,648
Weighted average remaining lease term (in years) (Year)	8 years	8 years 36 days
Weighted average discount rate	9.20%	9.20%

Note 10 - Leases - Future Minimum Lease Payments (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
2021	$ 2,297
2022	1,905
2023	1,842
2024	1,827
2025	1,367
Thereafter	5,574
Total lease payments	14,812
Less interest	(4,648)
Total operating lease liabilities	$ 10,164	$ 10,648

Note 11 - Capital Stock and Stock-based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Millions			3 Months Ended		12 Months Ended
	May 16, 2019	Apr. 02, 2018	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2000	Dec. 31, 2019	May 18, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date					85.00%
Increase In Number Of Shares Authorized For Issuance Under Stock Option And Incentive Plan (in shares)	350,000	3,400,000
Employee Stock Purchase Plan Shares Authorized (in shares)							1,400,000
Employee Stock Ownership Plan (ESOP), Shares in ESOP, Total (in shares)						1,081,404
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)			0
Employee Stock Ownership Plan, Shares Available for Issuance (in shares)			318,596
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)		20,908,929	275,419
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total			$ 3.3
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)			2 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)			$ 1.18
Deferred Compensation Arrangement with Individual, Maximum Contractual Term (Year)			10 years
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)			4,222,745	3,691,304
Deferred stock awards of Market Condition RSU, Approved 2019 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)			529,491
Maximum Percentage Of Target, Number of Restricted Stock Units			150.00%
Share-based Payment Arrangement, Option [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)			1 year
Share-based Payment Arrangement, Option [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)			4 years

Note 11 - Capital Stock and Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details)	3 Months Ended
	Mar. 31, 2020 $ / shares shares
Opening Balance, Stock Options Outstanding (in shares) \| shares	2,266,122
Options, Outstanding, Weighted Average Exercise Price (in dollars per share) \| $ / shares	$ 3.93
Options, Granted in Period (in shares) \| shares	42,373
Options, Granted in Period, Weighted Average Exercise Price (in dollars per share) \| $ / shares	$ 2.58
Options, Cancelled / Forfeited in Period (in shares) \| shares	(49,074)
Options, Cancelled / Forfeited, Weighted Average Exercise Price (in dollars per share) \| $ / shares	$ 3.81
Opening Balance, Stock Options Outstanding (in shares) \| shares	2,259,421
Options, Outstanding, Weighted Average Exercise Price (in dollars per share) \| $ / shares	$ 3.90
Restricted Stock Units (RSUs) [Member]
Restricted Stock Units Outstanding , Balance (in shares) \| shares	1,590,450
Restricted Stock Units Outstanding , Grant Date Fair Value, Balance (in dollars per share) \| $ / shares	$ 2.27
Restricted Stock Units, Granted in Period (in shares) \| shares	142,766
Restricted Stock Units Granted , Grant Date Fair Value, Balance (in dollars per share) \| $ / shares	$ 3
Restricted Stock Units, Vested in Period (in shares) \| shares	(267,588)
Restricted Stock Units, Vested , Grant Date Fair Value, Balance (in dollars per share) \| $ / shares	$ 2.75
Restricted Stock Units, Cancelled / Forfeited in Period (in shares) \| shares	(31,795)
Restricted Stock Units, Cancelled/ Forfeited , Grant Date Fair Value, Balance (in dollars per share) \| $ / shares	$ 3.02
Restricted Stock Units Outstanding , Balance (in shares) \| shares	1,433,833
Restricted Stock Units Outstanding , Grant Date Fair Value, Balance (in dollars per share) \| $ / shares	$ 2.24
Market Condition Restricted Stock Units [Member]
Restricted Stock Units Outstanding , Balance (in shares) \| shares	529,491
Restricted Stock Units Outstanding , Grant Date Fair Value, Balance (in dollars per share) \| $ / shares	$ 1.67
Restricted Stock Units, Granted in Period (in shares) \| shares
Restricted Stock Units Granted , Grant Date Fair Value, Balance (in dollars per share) \| $ / shares
Restricted Stock Units, Vested in Period (in shares) \| shares
Restricted Stock Units, Vested , Grant Date Fair Value, Balance (in dollars per share) \| $ / shares
Restricted Stock Units, Cancelled / Forfeited in Period (in shares) \| shares
Restricted Stock Units, Cancelled/ Forfeited , Grant Date Fair Value, Balance (in dollars per share) \| $ / shares
Restricted Stock Units Outstanding , Balance (in shares) \| shares	529,491
Restricted Stock Units Outstanding , Grant Date Fair Value, Balance (in dollars per share) \| $ / shares	$ 1.67

Note 11 - Capital Stock and Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based Compensation	$ 793	$ 591
Cost of Sales [Member] \| Continuing Operations [Member]
Share-based Compensation	10	13
Selling and Marketing Expense [Member] \| Continuing Operations [Member]
Share-based Compensation	51	(7)
General and Administrative Expense [Member] \| Continuing Operations [Member]
Share-based Compensation	696	551
Research and Development Expense [Member] \| Continuing Operations [Member]
Share-based Compensation	$ 36	$ 34

Note 11 - Capital Stock and Stock-based Compensation - Black Scholes Assumptions (Details) - Black Scholes Option Pricing Model [Member]	3 Months Ended
	Mar. 31, 2020
Volatility	54.83%
Risk-free interest rate	1.16%
Expected holding period (Year)	4 years 219 days

Note 11 - Capital Stock and Stock-based Compensation - Weighted Average Number of Shares (Details) - shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Basic (in shares)	38,328,791	37,644,684
Diluted (in shares)	38,328,791	37,644,684

Note 12 - Long Term Debt (Details Textual) $ in Thousands	3 Months Ended	12 Months Ended
Note 12 - Long Term Debt (Details Textual) $ in Thousands	Mar. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Jun. 30, 2020	Mar. 31, 2018 USD ($)	Jan. 31, 2018 USD ($)
Term Loan [Member]
Line of Credit Facility, Interest Rate at Period End	8.40%
Senior Secured Credit Facility [Member]
Debt Instrument, Quarterly Payment, Current Year				$ 400
Debt Instrument Quarterly Payment Next Year				600
Debt Instrument, Quarterly Payment, Thereafter				$ 800
Percentage of Consolidated Excess Cash Flow				50.00%
Excess Cash Flow Payment	$ 4,000
Excess Cash Flow Payment, Tranche Two		$ 4,000
Excess Cash Flow Payment, Tranche One		1,000
Limitation On Pledges of Capital Stock of Foreign Subsidiaries	65.00%
Senior Secured Credit Facility [Member] \| Maximum [Member]
Debt Instrument, Leverage Ratio	3.5
Senior Secured Credit Facility [Member] \| Maximum [Member] \| Forecast [Member]
Debt Instrument, Leverage Ratio			3.25
Senior Secured Credit Facility [Member] \| Base Rate [Member]
Debt Instrument, Basis Spread on Variable Rate	4.75%
Senior Secured Credit Facility [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate	6.25%
Senior Secured Credit Facility [Member] \| London Interbank Offered Rate (LIBOR) [Member] \| Minimum [Member]
Debt Instrument, Interest Rate, Stated Percentage	1.25%
Senior Secured Credit Facility [Member] \| London Interbank Offered Rate (LIBOR) [Member] \| Maximum [Member]
Debt Instrument, Interest Rate, Stated Percentage	4.25%
Senior Secured Credit Facility [Member] \| Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity					$ 25,000
Line of Credit Facility, Remaining Borrowing Capacity	$ 4,600
Term Loan [Member]
Long-term Debt, Gross	$ 50,168	$ 54,997
Term Loan [Member] \| Senior Secured Credit Facility [Member]
Long-term Debt, Gross					$ 64,000

Note 12 - Long Term Debt - Breakdown of Borrowings (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Total unamortized deferred financing costs	$ (1,081)	$ (1,180)
Total debt	49,087	53,817
Less: current installments	(3,200)	(3,200)
Less: excess cash flow sweep		(4,093)
Current unamortized deferred financing costs	393	393
Long-term debt	46,280	46,917
Term Loan [Member]
Long-term debt, gross	50,168	54,997
Line of Credit [Member]
Long-term debt, gross

Note 13 - Derivatives (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Jan. 31, 2018
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	$ 400
Interest Rate Swap [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Derivative, Fixed Interest Rate			2.72%
Interest Rate Swap [Member] \| PNC Bank [Member]
Derivative Asset, Notional Amount			$ 36,000
Term Loan [Member]
Long-term Debt, Gross	$ 50,168	$ 54,997
Senior Secured Credit Facility [Member] \| Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity			25,000
Senior Secured Credit Facility [Member] \| Term Loan [Member]
Long-term Debt, Gross			$ 64,000

Note 13 - Derivatives - Derivative Instruments (Details) - Interest Rate Swap [Member] - Cash Flow Hedging [Member] - USD ($)
$ in Thousands

Mar. 31, 2020

Dec. 31, 2019

Derivatives, notional amount

$ 27,289

Derivatives, fair value

^[1]

$ (747)

Other Assets [Member]

Derivatives, notional amount

$ 28,821

Derivatives, fair value

^[1]

$ (603)

[1]	See Note 14 for the fair value measurements related to these financial instruments.

Note 13 - Derivatives - Effect of Derivatives on AOCI (Details) - Interest Rate Swap [Member] - Cash Flow Hedging [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Amount of loss recognized in OCI on derivative	$ (216)	$ (196)
Interest Expense [Member]
Amount reclassified from AOCI into income	$ 72	$ 17

Note 14 - Fair Value Measurement - Assets and Liabilities Measured on a Recurring Basis (Details) - Interest Rate Swap [Member] - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Derivative liabilities	$ (747)	$ (603)
Fair Value, Inputs, Level 1 [Member]
Derivative liabilities
Fair Value, Inputs, Level 2 [Member]
Derivative liabilities	(747)	(603)
Fair Value, Inputs, Level 3 [Member]
Derivative liabilities

Note 15 - Other Current Liabilities - Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Compensation and payroll	$ 2,896	$ 2,554
Professional fees	567	395
Warranty costs	201	252
Local taxes, including VAT	91	345
Customer related costs	1,179	963
Interest	490	425
Other	2,025	1,157
Total	$ 7,449	$ 6,091

Note 16 - Revenues (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019	Dec. 31, 2018
Contract with Customer, Liability, Total	$ 3,673	$ 3,949	$ 3,715	$ 3,820

Note 16 - Revenues - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Total revenues	$ 23,771	$ 28,202
Instruments, Equipment, Software, and Accessories [Member]
Total revenues	22,937	26,757
Service, Maintenance, and Warranty Contracts [Member]
Total revenues	834	1,445
UNITED STATES
Total revenues	16,531	19,814
UNITED STATES \| Instruments, Equipment, Software, and Accessories [Member]
Total revenues	15,956	18,671
UNITED STATES \| Service, Maintenance, and Warranty Contracts [Member]
Total revenues	575	1,143
UNITED KINGDOM
Total revenues	2,711	3,319
UNITED KINGDOM \| Instruments, Equipment, Software, and Accessories [Member]
Total revenues	2,507	3,129
UNITED KINGDOM \| Service, Maintenance, and Warranty Contracts [Member]
Total revenues	204	190
GERMANY
Total revenues	2,612	3,010
GERMANY \| Instruments, Equipment, Software, and Accessories [Member]
Total revenues	2,573	2,913
GERMANY \| Service, Maintenance, and Warranty Contracts [Member]
Total revenues	39	97
Rest of the World [Member]
Total revenues	1,917	2,059
Rest of the World [Member] \| Instruments, Equipment, Software, and Accessories [Member]
Total revenues	1,901	2,044
Rest of the World [Member] \| Service, Maintenance, and Warranty Contracts [Member]
Total revenues	$ 16	$ 15

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Note 16 - Revenues - Changes in Deferred Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Balance	$ 3,949	$ 3,820
Deferral of revenue	531	956
Recognition of deferred revenue	(821)	(1,071)
Effect of foreign currency translation	14	10
Balance	3,673	3,715
Service [Member]
Balance	1,587	1,659
Deferral of revenue	308	845
Recognition of deferred revenue	(499)	(848)
Effect of foreign currency translation	14	10
Balance	1,410	1,666
Customer Advances [Member]
Balance	2,362	2,161
Deferral of revenue	223	111
Recognition of deferred revenue	(322)	(223)
Effect of foreign currency translation
Balance	$ 2,263	$ 2,049

Note 16 - Revenues - Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Balance, beginning of period	$ 325	$ 332
Provision for allowance for doubtful accounts	4	348
Charge-offs and other recoveries	(31)	(337)
Effect of foreign currency translation	(1)	(2)
Balance, end of period	$ 297	$ 341

Note 17 - Income Tax (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Tax Expense (Benefit), Total	$ 55	$ 576
Effective Income Tax Rate Reconciliation, Percent, Total	(1.20%)	(32.10%)

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.